摘要
目的探讨乙型肝炎病毒(HBV)基因型与抗病毒治疗的关系。方法回顾性分析164例慢性乙型肝炎(CHB)患者分别接受拉米夫定和干扰素治疗的临床效果,并对其与HBV基因型的关系进行探讨。结果使用拉米夫定抗病毒治疗时,C基因型的CHB患者HBV DNA和乙型肝炎病毒e抗原(HBeAg)血清转换率高于B基因型患者;使用干扰素进行抗病毒治疗时,B基因型患者的HBV DNA和HBeAg血清转换率及丙氨酸氨基转移酶(ALT)血清转阴率高于C基因型患者。结论拉米夫定治疗HBV C基因型CHB患者的疗效优于HBV B基因型患者,干扰素治疗HBV B基因型患者的疗效优于HBV C基因型患者。
ObjectiveTo investigate the relationship between the HBV genotypes and antiviral treatment. MethodsRetrospective analysis of 164 patients who were treated by lamivudine and interferon, and explore the clinical effect, then discuss the relationship between the HBV genotypes and antiviral treatment.Results When the patients were treated by lamivudine, HBV DNA and hepatitis B virus e antigen （HBeAg） serum conversion rate of C genotype was higher than B genotype; when the patients were treated by interferon, HBV DNA and HBeAg conversion rate and serum ALT serum overcast rate of B genotype is higher than C genotype. Conclusion When the patients were treated by lamivudine, the clinical effect of C genotype is better than B genotype; when the patients were treated by interferon, the clinical effect of B genotype is better than C genotype.
出处
《中国医学前沿杂志（电子版）》
2014年第5期139-141,共3页
Chinese Journal of the Frontiers of Medical Science(Electronic Version)
